Pediatric Drug Development: The International Conference on Harmonization Focus on Clinical Investigations in Children

  • M. Renée Simar


Recent public awareness and scientific advances have launched a reversal in the historical trend to virtually ignore the importance of obtaining reliable data from pediatric patients during the process of drug development. The need for well-designed clinical trials in children is now clearly recognized, and a few regulatory bodies have addressed the requirements for the conduct of these trials. Global consensus on the unique issues related to pediatric trials, however, has been lacking. The International Conference on Harmonization recently released a draft of its guideline, “Clinical Investigation of Medicinal Products in the Pediatric Population.” The objective of this paper is to discuss critical issues addressed by the guideline. It begins with a brief overview on the underlying need for the guideline and factors that have contributed to shifting attitudes toward the conduct of pediatric clinical trials. The five major considerations outlined in the guideline are then summarized. The discussion for each of the key areas is supplemented with background information, representative cases, and points for further consideration.

Key Words

Pediatric Global Guideline Drug development 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Statement by the Steering Committee. Second Steering Committee Meeting, International Conference on Harmonization. Tokyo. 1990.Google Scholar
  2. 2.
    Clinical Investigation of Medicinal Products in the Pediatric Population: Draft ICH Consensus Guideline. International Conference on Harmonisation. October 7, 1999.Google Scholar
  3. 3.
    Shirkey H. Therapeutic orphans. J Pediatr. 1968;72(1):119–120.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Gilman JT. Therapeutic drug monitoring in the neonate and paediatric age group: problems and clinical pharmacokinetic implications. Clin Pharmacokinet. 1990;19:1–10.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Kauffman RE, Kearns GL. Pharmacokinetic studies in paediatric patients: clinical and ethical considerations. Clin Pharmacokinet. 1992;23(1):10–19.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Samara E, Granneman R. Role of population pharmacokinetics in drug development: A pharmaceutical industry perspective. Clin Pharmacokinet. 1997;32(4):294–312.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Reed MD. Optimal sampling theory: an overview of its application to pharmacokinetic studies in infants and children. Pediatrics. 1999;104(5):627–632.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Blumer JL. Developmental pharmacology: past, present and future. Acta Paediatr Jpn. 1996;38(6):555–561.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Leeder JS, Kearns GL. Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am. 1997;44(1):55–77.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Therapeutic Products Directorate guidelines: Inclusion of pediatric subjects in clinical trials. Department of Health: Canada; August 1997.Google Scholar
  11. 11.
    Note for guidance on clinical investigation of medicinal products in children. CPMP/EWP/462/95. European Agency for the Evaluation of Medicinal Products; September 1997.Google Scholar
  12. 12.
    Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients: Final rule. Federal Register. 1998;63(231):66631–66672.Google Scholar
  13. 13.
    Report of the Working Party on Registration of Drugs in Children. Therapeutic Goods Administration, Australian Drug Evaluation Committee; October 1997.Google Scholar
  14. 14.
    Guidelines for the clinical evaluation of drugs in pediatric patients. Report to the Food and Drug Administration. American Academy of Pediatrics Committee on Drugs, 1998.Google Scholar
  15. 15.
    Nahata MC. Pediatric drug formulations: a rate-limiting step. Drug Inf J. 1999;33:393–396.CrossRefGoogle Scholar
  16. 16.
    Nahata MC. Lack of pediatric drug formulations. Pediatrics. 1999;104(3):607–609.PubMedGoogle Scholar
  17. 17.
    Manley MC, Oalman M, Sheiham A. A spoonful of sugar helps the medicine go down? Perspectives on the use of sugar in children’s medicines. Soc Sci Med. 1994;39:833–840.PubMedCrossRefGoogle Scholar
  18. 18.
    Schaefer HG, Michaelis I. Biopharmaceutical aspects of anti-infective therapy at the extremes of age. JAntimicrob Chemother. 1994;34(Suppl A):33–42.CrossRefGoogle Scholar
  19. 19.
    Committee on Drugs, American Academy of Pediatrics. Alternative routes of drug administration: advantages and disadvantages. Pediatrics. 1997;100(1):143–152.CrossRefGoogle Scholar
  20. 20.
    McRorie T. Quality drug therapy in children: formulations and delivery. Drug Inf J. 1996;30:1173–1177.CrossRefGoogle Scholar
  21. 21.
    Scott AWM. Non-medicinal ingredients. Drug Safety. 1990;5:95–100.PubMedCrossRefGoogle Scholar
  22. 22.
    Committee on Drugs, American Academy of Pediatrics. Inactive ingredients in pharmaceutical products: update. Pediatrics. 1997;99(1):268–278.CrossRefGoogle Scholar
  23. 23.
    Wax PM. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann Intern Med. 1995;15(122):6.Google Scholar
  24. 24.
    Lesko SM, Mitchell AA. Total bilirubin level in relation to excipients in parenteral morphine sulfate administered to seriously ill newborn infants. Paediatr Perinat Epidemiol. 1994;8(4):401–410.PubMedCrossRefGoogle Scholar
  25. 25.
    Leeder JS. Developmental aspects of drug metabolism in children. Drug Inf J. 1996;30:1135–1143.CrossRefGoogle Scholar
  26. 26.
    Marshall JD, Kearns GL. Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther. 1999;66(1):66–75.CrossRefGoogle Scholar
  27. 27.
    Finkelstein JW. The effect of developmental changes in adolescence on drug disposition. J Adolesc Health. 1994;15:612–618.PubMedCrossRefGoogle Scholar
  28. 28.
    Morselli PL. Clinical pharmacology of the perinatal period and early infancy. Clin Pharmacokinet. 1989;17(suppl 1):13–28.PubMedCrossRefGoogle Scholar
  29. 29.
    Stewart CF, Hampton EM. Effect of maturation on drug disposition in pediatric patients. Clin Pharm. 1987;6(7):548–564.PubMedGoogle Scholar
  30. 30.
    Simeon JG, Dinicola VF, Ferguson HB. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuro-Psychopharmacol Biol Psychiat. 1990;14:791–795.CrossRefGoogle Scholar
  31. 31.
    Geller B, Cooper TB, Graham DL, et al. Pharmaco-kinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year olds with major depressive disorder. J Am Acad Child Adolesc Psych. 1992;31(1):34–44.CrossRefGoogle Scholar
  32. 32.
    Bishai R, Taddio A, Bar-Oz B, et al. Relative efficacy of amethocaine gel and lidocaine-prilocaine cream for Port-a-Cath puncture in children. Pediatrics. 1999;104(3):e31.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Larsson BA, Tannfeldt G, Lagercrantz H, et al. Alleviation of the pain of venepuncture in neonates. Acta Paediatr. 1998;87(7):774–779.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Butler DR, Kuhn RJ, Chandler MHH. Pharmacokinetics of anti-infective agents in paediatric patients. Clin Pharmacokinet. 1994;26(5):374–395.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Gidding SS, Camp D, Flanagan, MH, et al. A policy regarding research in healthy children. J Pediatr. 1993;123:852–855.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    International Conference on Harmonization Good Clinical Practices: Consolidated Guideline. Federal Register. 1997;62(242):66113.Google Scholar
  37. 37.
    Walson PD. Patient recruitment: US perspective. Pediatrics. 1999;104(3):619–622.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Stein PR. Indices of pain intensity: construct validity among preschoolers. Pediatr Nurs. 1995;1995(21):2.Google Scholar
  39. 39.
    Pereira AL, Guijnsburg R, de Almeida MF, et al. Validity of behavioral and physiologic parameters for acute pain assessment of term newborn infants. Sao Paulo Med J. 1999;117(2):72–80.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Kemp JP. Study designs and challenges in clinical studies conducted in infants and children with asthma. J Allergy Clin lmunol. 1999;104(4 Pt 2):184–190.CrossRefGoogle Scholar
  41. 41.
    Santanello NC, Davies G, Galant SP, et al. Validation of an asthma symptom diary for interventional studies. Arch Dis Child. 1999;80(5):414–420.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Aylward GP. Understanding and treatment of childhood depression. J Pediatr. 1985;107(1):1–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Allen DB. Influence of inhaled corticosteroids on growth: a pediatric endocroinologist’s perspective. Acta Paediatr. 1998;87(2):123–129.PubMedCrossRefGoogle Scholar
  44. 44.
    Simar MR. Perinatal exposure to CNS-active medications: neurodevelopmental risks. CNS Drugs. 1999;12(6):451–470.CrossRefGoogle Scholar
  45. 45.
    Specific requirements on content and format of labeling for human prescription drugs; Revision of “Pediatric Use” Subsection in the Labeling; Final rule. Federal Register. 1994;59:64240.Google Scholar
  46. 46.
    Reed MD, Besunder JB. Developmental pharmacology: ontogenic basis of drug disposition. Pediatr Clin North Am. 1989;36(5):1053–1074.PubMedCrossRefGoogle Scholar
  47. 47.
    Berdcl D, Suverkrup R, Hermann G, et al. Total theophylline clearance in childhood: the influence of age-dependent changes in metabolism and elimination. Eur J Pediatr. 1987;146(1):41–43.CrossRefGoogle Scholar
  48. 48.
    Kearns GL. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr. 1995;7:220–233.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Ladd GW. Friendship patterns and peer status during early and middle childhood. Dev Behav Pediatr. 1988;9(4):229–237.CrossRefGoogle Scholar
  50. 50.
    Zarbatany L, Hartmann DP, Rankin DB. The psychological functions of preadolescent peer activities. Child Dev. 1990;61(4):1067–1080.PubMedCrossRefGoogle Scholar
  51. 51.
    Amiel SA, Sherwin RS, Simonson DC, et al. Impaired insulin in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med. 1986;315(4):215–219.PubMedCrossRefGoogle Scholar
  52. 52.
    Tercyak KPJ, Johnson SB, Kirkpatrick KA, et al. Offering a randomized trial of intensive therapy for IDDM to adolescents. Reasons for refusal, patient characteristics and recruiter effects. Diabetes Care. 1998;21(2):213–215.PubMedCrossRefGoogle Scholar
  53. 53.
    Litt IF, Cuskey WR. Compliance with medical regimens during adolescence. Pediatr Clin North Am. 1980;27(1):3–15.PubMedCrossRefGoogle Scholar
  54. 54.
    Vanelli M, Chiari G, Adinolfi B, et al. Management of insulin-dependent diabetes mellitus in adolescents. Horm Res. 1997;48(Suppl 4):71–75.PubMedCrossRefGoogle Scholar
  55. 55.
    Declaration of Helsinki, revised. World Medical Association. 35th World Medical Assembly, Venice. 1993.Google Scholar
  56. 56.
    Committee on Drugs, American Academy of Pediatrics. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics. 1995;95(2):286–294.Google Scholar
  57. 57.
    Convention on the Rights of the Child. UNGA Doc A/RES/44/25. United Nations Assembly; January 1989.Google Scholar
  58. 58.
    Weithorn LA, Scherer DG, Children’s involvement in research participation decisions: psychological considerations, In: Grodin MA, Glantz LH, eds. Children as Research Subjects: Science, Ethics and Law. New York: Oxford University Press; 1994:133–179.Google Scholar
  59. 59.
    Report and Recommendations: Research Involving Children. [OS]77-0004. Rockville, MD: Department of Health, Education and Welfare, National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research; 1977.Google Scholar

Copyright information

© Drug Information Association, Inc 2000

Authors and Affiliations

  • M. Renée Simar
    • 1
  1. 1.Clinical Operations, PPD DevelopmentCerveau ConsultingAustinUSA

Personalised recommendations